Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy

Osamu Takasawa, Naotaka Fujita, Go Kobayashi, Yutaka Noda, Kei Ito, Jun Horaguchi

Abstract

AIM: To assess optimum endoscopic biliary drainage (EBD) in cases with unresectable pancreatic cancer in the era of gemcitabine (GEM).

METHODS: Thirty patients with unresectable pancreatic cancer, who presented with jaundice and underwent chemotherapy using GEM after EBD were included in this study (GEM group). Fifteen cases with the same clinical manifestation and stage of pancreatic cancer treated with EBD alone were also included as controls. A covered metallic stent (CMS) or a plastic stent (PS) was used for EBD. The mean survival time (MST) in each group, risk factors of survival time, type of stent used and associated survival time, occlusion rate of stent, patency period of stent, and risk factors of stent occlusion were evaluated.

RESULTS: MST in the GEM group was longer than that in the control (9.9 mo vs 6.2 mo). In the GEM group, the survival time was not different between those who underwent metallic stenting and those who underwent plastic stenting. Stent occlusion occurred in 60% of the PS group and 7% of the CMS group. The median stent patency in the PS-GEM group and the CMS-GEM group was 5 mo and 7.5 mo, respectively. Use of a PS was the only risk factor of stent occlusion.

CONCLUSION: A CMS is recommended in cases presenting with jaundice due to unresectable pancreatic cancer, since the use of a CMS makes it possible to continue chemotherapy using GEM without repetition of stent replacement.

© 2006 The WJG Press. All rights reserved.

Key words: Gemcitabine chemotherapy; Endoscopic biliary drainage; Covered metallic stent; Pancreatic cancer; Unresectable pancreatic cancer; Obstructive jaundice

Takasawa O, Fujita N, Kobayashi G, Noda Y, Ito K, Horaguchi J. Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy. World J Gastroenterol 2006; 12(45): 7299-7303

http://www.wjgnet.com/1007-9327/12/7299.asp
Methods

GEM was administered in a standard manner, i.e., a drip infusion of 1000 mg/m² at a stable speed was given once per week for three consecutive weeks with an interval of one week between courses. After confirming a decrease in the serum total bilirubin level of 20 mg/L or less, administration of GEM was started. When some adverse events occurred, administration of GEM was postponed or its dose was reduced. Adverse effects were evaluated following National Cancer Institute Common Terminology Criteria for Adverse Events ver.3.0 (CTCAE). The stents used were covered expandable metallic stents 10 mm in caliber (covered biliary Wallstent, Boston Scientific Co.) (CMS) and plastic stents 10 Fr in diameter (Double Layer Biliary Stent, Olympus Co.) (PS). In the GEM group, CMS was placed in 15 patients (CMS-GEM group) and PS was applied in the remaining 11 (PS-alone group). In the control group, CMS was deployed in 4 patients (CMS-alone group), while PS was applied in the remaining 11 (PS-alone group). The period of stent patency was measured from the day of stenting to the day when the initial occlusion was diagnosed. Stent occlusion was defined as development of cholangitis or jaundice with abnormalities in laboratory tests indicating bile stasis. When a PS has clogged and the duration from placement of PS to its occlusion was regarded as the patency period of PS. As for survival time, the total period was counted as PS in such cases. In the CMS group, when the stent was occluded and was replaced with a PS, the duration between the initial stenting and the second stenting was measured as the patency period of CMS, and the total time until death was regarded as the survival time for this group. The median survival time (MST) was calculated based on the definition of survival time as the time from the day of hospitalization to that of death or the last date of confirmed survival. The following were evaluated: (1) MST of the GEM group and the control, (2) prognostic factors, (3) correlation between the stent applied and survival time, (4) occlusion rate and patency of stents, (5) risk factors of stent occlusion, and (6) complications of stenting and adverse events of GEM.

Statistical analysis

Stat View v5.0 was used for statistical analysis. Comparison of the two groups was carried out using the Chi-square test, the unpaired t test (Student’s t test), or the Mann-Whitney U test, MST and the median patency time of stents were evaluated by the Mantel-Cox log rank test of the Kaplan-Meier curves. For the analysis of the risk factors of stent patency and survival, univariate analysis by Cox’s proportional hazard model followed by multivariate analysis was performed.

RESULTS

The mean survival time in the GEM group and the control was 9.9 mo and 6.2 mo, respectively (9.87 ± 0.33 vs 6.23 ± 0.93, P = 0.004, Figure 1). The following were listed as prognostic factors of survival by univariate analysis: clinical stage of pancreatic cancer (Ⅳa vs Ⅳb, P = 0.02; OR = 2.36; 95% CI, 1.15-4.84), liver metastasis (+ vs -, P = 0.01; OR = 2.55; 95% CI, 1.24-5.22), and GEM treatment (+ vs -, P = 0.01, OR = 2.72; 95% CI, 1.35-5.48) (Table 2). Multivariate analysis, however, revealed that none of these prognostic factors had reached the level of significance. The survival curves of the PS group and the CMS group with/without GEM are shown in Figures 2 and 3. There were significant difference between the PS-alone group and the CMS-GEM group (5.53 ± 0.94 vs 10.1 ± 2.70, P = 0.02), as well as between the PS alone group and the CMS-GEM group (5.53 ± 0.94 vs 9.87 ± 0.43, P = 0.001). The difference between the CMS-GEM group and the PS-GEM group was not significant (9.87 ± 0.43 vs 10.1 ± 2.70, P = 0.26, Figure 4). Stent obstruction was observed more frequently in the PS group than in the CMS group (PS vs CMS, P = 0.0002; OR = 26.4; 95% CI, 11.4-14.6). Only one patient developed stent occlusion (1/15, 7%), which was due to overgrowth of the tumor in the CMS-GEM group; this was treated by additional PS stenting. The stent patency in the PS-GEM group and PS-alone group was 5.0 mo and

| Table 1 Patients characteristics |
|----------------------------------|
|                                  |
| GEM group | Control group |
| n = 30     | n = 15        | P       |
| Age (yr)  | 61 ± 10       | 67 ± 8   | 0.06    |
| Male/Female | 21/9        | 7/8     | 0.13    |
| Stage (Ⅳa/Ⅳb) | 22/8    | 7/8     | 0.08    |
| PS/CMS | 15/15        | 11/4    | 0.32    |

GEM: gemcitabine; PS: plastic stent; CMS: covered expandable metallic stent.

1The PS was exchanged to CMS after occlusion in 4 patients.

| Table 2 Prognostic factors of survival by univariate analysis |
|-------------------------------------------------------------|
|                              | OR  | 95% CI       | P       |
| Age | 1.03 | 1.00-1.06     | 0.08    |
| Gender (Female) | 1.56 | 0.81-2.99     | 0.18    |
| Stage (Ⅳb) | 2.36 | 1.15-4.84     | 0.02    |
| Liver metastasis (+) | 2.55 | 1.24-5.22     | 0.01    |
| Gemcitabine (-) | 2.72 | 1.35-5.48     | 0.01    |

(4) occlusion rate and patency of stents, (5) risk factors of stent occlusion, and (6) complications of stenting and adverse events of GEM.
4.5 mo, respectively (5.00 ± 2.26 vs 4.53 ± 1.31, P = 0.59, Figure 5). Compared with these two groups, the CMS-GEM group showed a patency of 7.5 mo (not reached) (5.00 ± 2.26 vs 7.49 ± 0.82, P = 0.03 and 5.00 ± 4.53 vs 1.31 ± 0.82, P = 0.01, respectively, Figures 6 and 7). Univariate analysis revealed use of a plastic stent to be the only risk factor of stent occlusion (P = 0.01; OR = 4.7; 95% CI, 1.48-15.4, Table 3). One patient each in the CMS-GEM and the CMS-alone groups developed acute cholescystitis. Either dislodgement of a stent or development of acute

Figure 2 Survival curves of CMS-GEM and PS-alone groups (9.87 ± 0.43 vs 5.53 ± 0.94, P = 0.001).

Figure 3 Survival curves of PS-GEM and PS-alone groups (10.1 ± 2.70 vs 5.53 ± 0.94, P = 0.02).

Figure 4 Survival curves of CMS-GEM and PS-GEM groups (9.87 ± 0.43 vs 10.1 ± 2.70, P = 0.26).

Figure 5 Stent patency in PS-GEM and PS-alone groups (5.00 ± 2.26 vs 4.53 ± 1.31, P = 0.59).

Figure 6 Stent patency in CMS-GEM and PS-GEM groups (7.49 ± 0.82 vs 5.0 ± 2.26, P = 0.03).

Figure 7 Stent patency in CMS-GEM and PS-alone groups (7.49 ± 0.82 vs 4.53 ± 1.31, P = 0.01).
pancreatitis after stent placement was observed. In the GEM group, 24 patients (89%) showed adverse effects of GEM on the bone marrow system, these effects benign grade 3 or greater in 4 patients. Reduction of the dose of GEM was necessary in 3 patients due to bone marrow suppression and in 7 due to digestive symptoms such as nausea and anorexia. Finally, administration of GEM was abandoned due to adverse effects in 4 patients (Table 4).


discussion

Before starting chemotherapy, biliary drainage is mandatory in patients with unresectable pancreatic cancer who present with obstructive jaundice. Endoscopic biliary drainage (EBD) is now widely used for such purpose. Many studies have been published on the selection of stents in EBD[1-3]. With regard to PS, development of Teflon stents[4,10] has not been able to prolong the patency period much longer than that of polyethylene stents[5,11-13]. Many a study has revealed the patency of metallic stents to be longer than that of PS[1-3]. The reported patency is 3-5 mo for PS[1,3,5,14] and nearly 9 mo for metallic stents[1-3,14]. In current clinical practice, stent selection is based on the stage of malignancy and expected prognosis. Distant metastasis, tumor size, and local extension are considered to be prognostic factors[15-17]. In cases with short life expectancy (4-6 mo or less), such as in advanced pancreatic cancer, occlusion of PS usually does not occur before death, and application of PS is considered to be adequate from the viewpoint of cost-effectiveness as well[2,3,6,8]. Thus far, chemotherapy, radiation and chemoradiotherapy have been performed for patients with unresectable pancreatic cancer, which necessitates hospitalization. However, the results have been quite unsatisfactory. Development of GEM has had an impact on the treatment. Rothenburg et al[18] reported significant prolongation of survival with GEM in their phase II study of patients in whom 5-FU was not effective. Burris et al[19] carried out a randomized controlled trial on the comparison of GEM with 5-FU in cases without previous chemotherapy, and reported that although mass reduction was observed in only 5.4% of the cases, alleviation of symptoms was achieved in 23.8% with a significant difference. The survival time was also significantly prolonged in the patient group treated with GEM compared with that in the 5-FU group. GEM is given to patient by drip infusion at a stable speed that requires a relatively short time without critical side effects, enabling its administration on an outpatient basis. Shortening of the period of hospitalization is quite meaningful for patients with poor prognoses. In this study, prolongation of MST by GEM in patients with stage IV pancreatic cancer was confirmed. With respect to MST, there was no difference between the CMS-GEM group and the PS-GEM group. However, stent occlusion developed more frequently in the PS-GEM group than in the CMS-GEM group (60% vs 7%). Stent occlusion may necessitate postponement of administration of GEM and requires additional intervention or hospitalization, which leads to deterioration of the patient’s QOL. Possible influences of GEM on the patency of stents are prolongation of patency by controlling the tumor mass and shortening of patency by clogging subsequent to biliary infection induced by bone marrow suppression. As the comparison of stent patency in the PS-GEM group and that in the PS-alone group showed no difference, GEM may have no or only a subtle effect on the stent patency. Acute cholecystitis, which was managed conservatively, was the only complication relevant to stenting. Discontinuance of GEM due to adverse effects was necessary in only 16% of the patients. When compared to that of the PS group, the stent patency of the CMS-GEM group was longer. It is expected that those patients who are to undergo GEM will have a longer survival than that before GEM was available. The significance of the maintenance of stent patency is much greater than before as it can eliminate readmission due to stent occlusion and postponement of GEM. Development of effective chemotherapy, including a combination of some agents, will further extend the significance of longer stent patency further. The selection of stents should be reassessed from this point of view. Based on the data shown here, we suggest that the use of CMS should be considered in patients with unresectable pancreatic cancer presenting with jaundice that are to undergo GEM. Further studies including cost-benefit assessment and a randomized, prospective comparison trial with metallic and plastic stents are necessary.

References

1. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction.
endoscopic biliary drainage for GEM

[References]

1. Wagner HJ, Pausch J, Vakil N. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. *Endoscopy* 1993; 25: 212

2. Knyrim K, Wagner HJ, Pausch J, Vakil N. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. *Endoscopy* 1993; 25: 212

3. Lammer J, Hausegger KA, Füllkrüger F, Winkelbauer FW, Wildling R, Klein GE, Thurnher SA, Havelec L. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. *Radiology* 1996; 201: 167-172

4. Binmoeller KF, Seitz U, Seifert H, Thonke F, Sikka S, Soehendra N. The Tannenbaum stent: a new plastic biliary stent without side holes. *Am J Gastroenterol* 1995; 90: 1764-1768

5. van Berkel AM, Boland C, Redekop WK, Bergman JJ, Groen AK, Tytgat GN, Huibregtse K. A prospective randomized trial of Teflon versus polyethylene stents for distal malignant biliary obstruction. *Endoscopy* 1998; 30: 681-686

6. Pereira-Lima JC, Jakobs R, Maier M, Benz C, Kohler B, Riemann JF. Endoscopic biliary stenting for the palliation of pancreatic cancer: results, survival predictive factors, and comparison of 10-French with 11.5-French gauge stents. *Am J Gastroenterol* 1996; 91: 2179-2184

7. Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. *Gastrointest Endosc* 1998; 47: 1-7

8. Yeoh KG, Zimmerman MJ, Cunningham JT, Cotton PB. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. *Gastrointest Endosc* 1999; 49: 466-471

9. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). December 12, 2003; 1-72. Available from: URL: http://ctep.cancer.gov/reporting/ctc_v30.html

10. van Berkel AM, Bruno MJ, Bergman JJ, van Deventer SJJ, Tytgat GN, Huibregtse K. A prospective randomized study of hydrophilic polymer-coated polyurethane versus polyethylene stents in distal malignant biliary obstruction. *Endoscopy* 2003; 35: 478-482

11. Terruzzi V, Comin U, De Grazia F, Toti GL, Zambelli A, Beretta S, Minoli G. Prospective randomized trial comparing Tannenbaum Teflon and standard polyethylene stents in distal malignant biliary stenosis. *Gastrointest Endosc* 2000; 51: 23-27

12. England RE, Martin DF, Morris J, Sheridan MB, Frost R, Freeman A, Lawrie B, Deakin M, Fraser I, Smith K. A prospective randomised multicentre trial comparing 10 Fr Teflon Tannenbaum stents with 10 Fr polyethylene Cotton-Leung stents in patients with malignant common duct strictures. *Gut* 2000; 46: 395-400

13. van Berkel AM, Huibregtse IL, Bergman JJ, Rauws EA, Bruno MJ, Huibregtse K. A prospective randomized trial of Tannenbaum-type Teflon-coated stents versus polyethylene stents for distal malignant biliary obstruction. *Eur J Gastroenterol Hepatol* 2004; 16: 213-217

14. Ito K, Fujita N, Noda Y, Kobayashi G, Kimura K. Plastic stent placement for unresectable malignant biliary stricture. *Digestive Endosc* 2004; 16: 43-45

15. Hoepffner N, Forster EC, Högemann B, Domschke W. Long-term experience in Wallstent therapy for malignant choledochal stenosis. *Endoscopy* 1994; 26: 597-602

16. Prat F, Chapat O, Ducot B, Ponchon T, Fritsch J, Choury AD, Pelletier G, Buffet C. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. *Gut* 1998; 42: 76-80

17. Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, Canard JM, Fritsch J, Rey JF, Burtin P. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. *Gastrointest Endosc* 2003; 57: 178-182

18. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, von Hoff DD. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. *Ann Oncol* 1996; 7: 347-353

19. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; 15: 2403-2413

S-Editor Wang GP L-Editor Rippe RA E-Editor Ma WH